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Abstract
Background—There has been considerable debate regarding what typically occurs after 
experimentation with drugs throughout the life of young people who used various drugs.
Aims—To evaluate the clinical importance of the most common sequence for the first use of a 
drug by two models(the ‘gateway model’ and the ‘alternative model’, which is the most popular 
sequence for Brazilian university students according to a previous study) regarding the 
problematic use of alcohol, tobacco, cannabis and other illegal drugs, assessed by ASSIST.
Method—People who had already experimented with three or more drugs across different stages 
of the two models were selected from a representative sample of university students from 27 
Brazilian capitals(n=12, 711).
Findings—There were no differences regarding the problematic use of the most consumed drugs 
in Brazil(alcohol, tobacco and cannabis) between the models. Multiple drug seekers and violators 
had more problematic use of illegal drugs other than cannabis than individuals in the model 
sequence. However, in the case of violators, this was only evident in the alternative model.
Conclusions—Multiple drug seekers and violators deserve special attention due to their 
increased risk of problematic use of other illegal drugs.
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The ‘Gateway model’(Kandel, 1975) predicts that the use of alcohol and/or tobacco occurs 
during the first step, followed by cannabis in the second step and other illegal drug use in the 
third step*. Alcohol and tobacco are usually the first drugs that adolescents experiment with, 
according to several international studies(Van Etten et al., 1997, Wagner & Anthony, 2002, 
Herrera-Vazquez et al., 2004, Wells & McGee, 2008, Caris et al., 2009, Mayet et al., 2010), 
which may be why these two drugs have the highest prevalence of use over the lifespan in 
most countries. The second step generates more controversial data. In countries with a high 
prevalence of cannabis use, such as Germany, Ukraine and New Zealand, the classic 
sequence seems to be most common(Degenhardt et al, 2010). Violators are those individuals 
who try alcohol, tobacco or cannabis after first experimenting with other drugs or who 
experiment with alcohol or tobacco after cannabis. In the U.S., one study showed that one of 
these violations was more common in a specific ethnic group(Vaughn et al., 2008).
There is another category, namely that of people who in theory, actively experiment with 
new drugs. Curiosity may be an important factor in the drug experimentation of these 
individuals(Yang et al, 2009). These people experiment with drugs from different steps(e.g., 
cocaine and alcohol) within a short time interval(<1 year). For this group, the sequence of 
drug use experimentation loses importance, and they are best characterised as a separate 
group. Wagner & Anthony(2002) defined this group as ‘drug seekers’.
Recently, our group investigated the most common sequences of drug use in the Brazilian 
university student population(Author 1 et al., 2013). This previous study found the most 
common sequence of drug use in this population to be the following: alcohol and/or tobacco 
use in the first step, cannabis and/or inhalants in the second step, and other drugs in the third 
step. In the present study this proposal is referred to as the ‘Alternative model’†.
As adolescence usually involves the first use of several drugs, the subsequent period, during 
which many individuals attend a university, is an interesting one within which to assess the 
age of first drug use in general, given that most drug use initiations have occurred recently, 
which minimises memory bias. Bearing this in mind, the present study seeks to investigate 
whether the most common sequence correlates with the problematic use of any specific 
drug(s) among Brazilian university students.
2.Methods
The project was previously evaluated and approved by the local Institutional Review 
Board(IRB). Data collection was completed between May–December of 2009.
*In the last decade, there has been considerable debate about what typically occurs regarding experimentation with drugs sequencing 
pattern throughout the life of young people who used various drugs(Morral et al., 2002, Fergusson et al., 2006). This debate has been 
rekindled because of recent data from a study with laboratory animals that found the previous use of a legal substance(e.g., nicotine) 
increased the likelihood of becoming addicted to an illegal substance(e.g., cocaine) after its first use(Levine et al., 2006), but the 
reverse pattern was not found. Moreover, recent cross-national epidemiological data suggest that instead of finding a single universal 
sequence, the incorporation of the characteristics of each population will determine the most common sequence(Degenhardt et al., 
2010) for that population.†This model is consistent with the moderately high lifetime prevalence of inhalant use(24.6%), which is similar to that of cannabis 
use(35.4%) within this population(Wagner et al., 2007). The moderately high prevalence of inhalant lifetime use is a feature of the 
general population in Brazil,(Fonseca et al, 2010).
Castaldelli-Maia et al. Page 2










The target population of this study was university students who were enrolled in 
undergraduate courses at Higher Education Institutions(HEIs), both public and private, in 
the 27 Brazilian state capitals. Undergraduate degrees take approximately 4 to 6 years to 
complete in Brazil. After agreeing to participate, students completed and signed an informed 
consent statement. There was no incentive to participate and they were not part of their 
course. A random sample was stratified and recruited with clusters of unequal sizes‡.
2.2.Measures
A structured, self-administered, anonymous questionnaire consisting of 98 closed questions 
was developed with an emphasis on drug use and related disorders, risky behaviours and 
screening for psychiatric morbidity(e.g., depressive symptoms and psychotic and 
nonspecific psychological complaints). The content of this questionnaire was based on the 
World Health Organization’s research questionnaire(Andrade et al., 1997, Stempliuk et al., 
2005).
2.3.Drug Use
The data on drug use were collected through a series of questions with multiple response 
options. First, students reported whether they had ever used the following drugs: alcohol, 
tobacco, cannabis, inhalants and solvents, cocaine, hallucinogens, ketamine, ayahuasca, 
ecstasy, steroids, tranquilisers, prescription opioids, anticholinergics, heroin, amphetamines, 
and synthetic drugs. In the second part of the questionnaire, students reported the age that 
they first used each of the previous drugs. In addition, the ASSIST (Alcohol, Smoking and 
Substance Involvement Screening Test) was applied for each drug.
2.3.1.Division of the polydrug user groups—Figure 1 presents the division of 
individuals by the type of sequence of their first drug use. Analyses were performed with 
two different forms of group separation for the polydrug users depending on their sequences 
of first use of the drugs. The individual could then be allocated into one of the following 
three groups:(i)model sequencers(MS), meaning s/he passed through the stages in the order 
of the sequence;(ii)violators(VT), meaning s/he passed through the stages in a different 
order than the sequence; or(iii)multiple drug seeker(MDS), meaning s/he used two drugs 
from different stages at the same age. The two methods of dividing the sample were as 
follows:
• ‘Gateway model’: Stage 1-Alcohol and/or Tobacco; Stage 2–Cannabis; Stage 3-
Other Drugs.
• ‘Alternative model’: Stage 1-Alcohol and/or Tobacco; Stage 2–Cannabis and/or 
Inhalants; Stage 3-Other Drugs
‡The sampling was conducted in two stages, such that a sample of HEIs was selected, and a sample of student classes was chosen 
from this selection. Given that the sizes of the HEIs and the classes(in terms of the number of universities) were not always the same, 
the conglomerates were of unequal sizes. The final response rate for this study was approximately 72.1% when the estimated size of 
the college student sample was taken into consideration(12, 721/17, 651). The analysis of the survey data complied with the following 
characteristics of the sampling plan:(i)a complex sample,(ii)the use of stratification,(iii)clustering and(iv)dissimilar selection 
probabilities. The dissimilar selection(DM) probability was one aspect of the sampling plan that was considered when analysing the 
data. Two weighting factors were obtained to deal with DM.
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With regard to the age of first use of drugs, there were a significant number of people who 
did not declare all of the ages necessary, which excluded them from the analyses§.
2.3.2.The ASSIST scores—The ASSIST instrument is translated and validated for the 
Portuguese language, which is spoken in Brazil(Henrique et al., 2004). First, we calculated 
the ASSIST scores for all drugs for all of the individuals. Then, these values were stratified 
into the following two tracks:(i) normal use – 0 to 3 points; or(ii) problematic use – 4 points 
or more(which merge risk of abuse and dependence). We combined the ASSIST scores for 
illegal drugs other than cannabis into a single class called ‘other drugs’ as follows: if an 
individual obtained a problematic score on a drug, he would be allocated into the range of 
ASSIST problematic. An individual should have a normal ASSIST score for all of the drugs 
included in this class to be considered as a ‘normal user’.
2.4.Statistical analysis
We used the statistical package STATA version 11 to run the analyses. All of the analyses 
were performed within the survey option with weights, strata and primary sampling units. 
Differences were considered valid at the p<0.05 level. Initially, we ran a descriptive analysis 
with chi-square tests. We selected all of the people who had used alcohol to analyse for 
possible differences in ASSIST scores that were stratified by alcohol among the three groups 
and then comparing each group against each other in pairs. The same procedure was 
followed for tobacco, cannabis and other drugs. Data were analysed using logistic regression 
models for categorical outcomes with the inclusion of 14 socio-demographic variables: 
gender, age, religion, practice of the religion, years of education of the head of the family, 
ethnic group, marital status, children, employment status, driver license, area of the 
undergraduate course, year of the undergraduation, happy with the undergraduation course, 
and all-day course.
3.Results
The majority of MS were male in both models (67.8% in the ‘Gateway model’ and 60.2% in 
the ‘Alternative model’) while the opposite was true for VT(male were 42.2% and 31.1%, 
respectivelly). MDS were more balanced between the two genders. Regarding age, the 
majority of MS, VT and MDS in both models were older than 21 year-old. Figure 1 presents 
the division of the groups following the criteria for the ‘Gateway model’ and the 
‘Alternative model’.
3.1.Gateway model
Table 1 presents the results of the descriptive analyses with chi-squared test according to the 
classical model. Regarding the problematic use of alcohol and tobacco, there was no 
difference between groups. However, in relation to the problematic use of cannabis, there 
were differences among the three groups. When the groups were analysed in pairs, there was 
§Figure 1 presents the number of people in each group. A logistic regression with an adjustment for socio-demographic variables was 
run to determine whether there were significant differences between the individuals who declared all of the ages(and were included in 
the study) compared with those who did not. Additionally, people who declared all of their ages of first use did not complete all of the 
questions on the ASSIST and were therefore excluded from the analysis(Figure 1). Only minor differences were found between 
individuals included in the study and those excluded because of missing data for both models(‘Gateway’ and ‘Alternative’).
Castaldelli-Maia et al. Page 4









more problematic use of cannabis among the MS(35.8%) compared to the VT(18.2%) with p 
<0.05. A difference was also evident in the MS(35.8%) compared with the MDS(18.0%) 
with p<0.05. There was a reverse situation regarding the problematic use of other drugs. 
MDS had more problematic use(27.9%) than the MS(16.3%) with p<0.05.
After the inclusion of several socio-demographic variables in the logistic regression 
models(table 2), it is evident that all of the differences in the problematic use of cannabis 
were not supported given that the 95% confidence intervals passed through 1.00. The only 
difference that remained significant was regarding the problematic use of other drugs in 
MDS compared to the MS(aOR=8.52, 95%CI=1.20–60.27, p<0.05) with greater problematic 
use in the MDS.
3.2.Alternative model
Table 1 presents the many statistically significant differences that were found in the 
descriptive analyses using chi-squared test according to the ‘Alternative model. There were 
no significant differences between MDS and VT regarding problematic use of 
alcohol(63.9% and 69.9%, respectively). However, problematic use of alcohol occurred in 
83.5% of MS, which was significantly different from the VT(p<0.01) and the MDS(p<0.01), 
and the difference among all the groups was also significant(p<0.01). With regard to 
problematic use of tobacco, there was no significant difference between the MS and the 
MDS(49.3% versus 45.4%, p > 0.05). However, 26.6% of the VT had problematic use of 
tobacco, which was significantly different from the MS(p<0.01) and the MDS(p<0.01), and 
a significant difference was found among all of the groups(p<0.01). Regarding problematic 
use of cannabis, all the analyses generated significant differences(p<0.05), with 35.8% of 
the MS, 9.3% of the VT and 17.6% of the MDS reporting problematic use of that drug. The 
problematic use of other drugs was higher in the MDS(41.7%) than the VT(29.4%) and the 
MS(20.3%), leading to significant differences between all of the groups(p<0.001). This 
difference was only confirmed between MDS and MS(p <0.001).
None of the significant findings in the exploratory analyses were significant in the logistic 
regression models(table 2). Regarding the use of alcohol, tobacco and cannabis, all of 
analyses generated 95% confidence intervals that encompassed 1. However, there were 
significant differences in the problematic use of other drugs between the MDS and the 
MS(aOR=5.10, 95%CI=1.65–15.78, p<0.01), with higher problematic use in the MDS, and 
between the VT and the MS(aOR=0.31, 95%CI=0.11–0.91, p<0.05), with more problematic 
use in the VT.
4.Discussion
The aim of this study was to compare the prevalence of an unfavourable clinical 
outcome(i.e., the problematic use of alcohol, tobacco, cannabis and other drugs) among 
three groups of polydrug users with different trajectories in a representative sample of 
university students from the 27 Brazilian capitals. These polydrug users were divided by the 
most common paths for drug use in the U.S.(i.e., the ‘Gateway model’)(Kandel, 1975) and 
for Brazilian university students(i.e., the ‘Alternative model’)(Author 1 et al., 2013), 
according to previous studies. There were no differences in the problematic use of the three 
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most consumed psychoactive substances in Brazil(Fonseca et al., 2010), which are alcohol, 
tobacco and cannabis, according to either model. However, MDS had more problematic use 
of other drugs, which are drugs other than alcohol, tobacco and cannabis, than those 
individuals in the classical sequence in both models. In addition, when using the ‘Alternative 
model’, there was more problematic use of other drugs in VT than in the MS, which argues 
for including the characteristics of each population when studying the sequences of drug 
use.
Although several studies have evaluated the transitions of first drug use in several 
countries(Van Etten et al, 1997, Herrera-Vazquez et al., 2004, Wells & McGee, 2008, Caris 
et al., 2009, Chen et al., 2009, Posada-Villa et al., 2009, Makanjuola et al., 2010, 
Degenhardt et al, 2010, Mayet et al., 2010, Author 1 et al., 2013) and have presented how 
the use of one drug increases or decreases the chances of using a second drug, little to no 
literature compares the clinical outcomes of the different groups of polydrug users. 
Recently, Tarter et al.(2012) presented the results of a prospective study that followed 
people from 10–22 years of age, which were similar to ours regarding cannabis. The most 
common sequence for experimenting with drugs(i.e., illegal drug use before the use of 
cannabis) had no effect on the problematic use of cannabis later. Their study did not 
consider the last step of the classical sequence(i.e., cannabis use before the use other illegal 
drugs), which was examined in this study. In a cross-sectional study of individuals from the 
U.S.(Degenhardt et al, 2009) ‘Gateway model’ violations were largely unrelated to later 
dependence risk, with the exception of small increases in risk of alcohol and other illegal 
drug dependence for those who initiated use of other illegal drugs before cannabis. In this 
study, the clinically unfavourable outcome of dependence was assessed with the Composite 
International Diagnostic Interview(CIDI), and only the ‘Gateway model’ was considered. 
Our study was different in that we used the ASSIST and combined the suggestive use of 
abuse and dependence into one single class(problematic use). We also created one group 
consisting of different polydrug users, which were the MDS, and we analysed two 
models(i.e., the ‘Gateway’ and ‘Alternative‘ ones). With regard to the comparable data 
between the two studies, which involves the differences between the VT and MS, we did not 
find a clinically unfavourable outcome(problematic use) of alcohol, but did find of illegal 
drug.
We must remember that although it is a representative sample of university students from 
the 27 capitals of a country with diverse cultural, economic and social differences(Victora et 
al., 2010), we are still dealing with a specific population. University students in this country 
are not representative of the general population given that only 13.9% of young adults have 
access to higher education. Almost 50% of university students study in private institutions, 
which sets them apart from the general population. Furthermore, cross-sectional data like 
this are especially prone to a memory bias, which in this case may affect the memory of the 
exact date of the first use of drugs. However, as previously noted, given that most of 
experimentation with drugs occur in adolescence and early adulthood, examining students 
attending a university is the best time period as it may attenuate this bias. Still, as one would 
expect, there were a lot of people who did not remember all of the ages of their first use, yet 
a statistical comparison showed that there were no differences regarding the use of the most 
popular drugs.
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Studies in other populations should be conducted to test this hypothesis. In addition, the role 
of psychiatric comorbidity could be investigated regarding drug use sequencing pattern. 
Moreover, VT of the classical sequence, when considering the most common sequence for 
each country, may have an increased risk of pathological use of illegal drugs other than 
cannabis. These data also need further study to analyse different countries’ cultures. 
Interventions, such as secondary prevention, could be particularly interesting for MDS and 
VT.
In practical terms, careful attention must be paid to two aspects of the present study. Firstly, 
this study suggests that three types of individuals have an elevated risk of ‘other drugs’ 
abuse/dependence:(i)those who experiment with cannabis/inhalants before alcohol/tobacco;
(ii)those who experiment with ‘other drugs’ before alcohol/tobacco/cannabis/inhalants; and 
those who experiment with drugs from a different step for a short period(<1 year). Secondly, 
our results show that a large number of the university students went through the three steps 
of the two models of experimentation with drugs. These findings deserve special attention 
by health policy makers and practitioners. Strang et al.(2012) suggested brief interventions 
targeted at select groups who have a higher risk of drug problems. This approach seems to 
suit individuals who experiment with many drugs within a short period of time, as well as 
those who violate the most classical drug experimentation sequence for Brazilians who 
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Distribution of samples per type of model and sequence of drug use among Brazilian 
university students, 2009.
*In this criteria, alcohol or tobacco use meant just an unique drug use
**In this criteria, alcohol or tobacco use meant just an unique drug use, and cannabis or 
inhalants use meant just another unique drug use
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Table 2
Results of logisitic regression on two drug experimentation models among a representative sample of 
Brazilian university students, 2009.
Gateway model Logisitic Regression**
ASSIST All groups MS* versus VT* VT* versus MDS* MDS* versus MS*
Alcohol
aOR 0.68 0.50 0.66 0.79
95%CI 0.46–1.01 0.18–1.41 0.43–1.02 0.45–1.38
p 0.061 0.192 0.062 0.418
Tobacco
aOR 0.91 1.20 0.99 0.45
95%CI 0.61–1.35 0.48–2.99 0.75–1.30 0.08–2.48
p 0.647 0.686 0.981 0.356
Cannabis
aOR 0.82 0.80 0.86 0.56
95%CI 0.58–1.15 0.34–1.86 0.63–1.16 0.17–1.87
p 0.250 0.609 0.331 0.349
Other drugs
aOR 1.01 0.45 0.96 8.52
95%CI 0.67–1.51 0.19–1.05 0.69–1.33 1.20–60.27
p 0.954 0.066 0.807 0.032
Alternative model Logisitic Regression**
ASSIST All groups MS* versus VT* VT* versus MDS* MDS* versus MS*
Alcohol
aOR 1.01 0.92 0.98 0.91
95%CI 0.73–1.40 0.44–1.90 0.68–1.41 0.50–1.66
p 0.915 0.823 0.935 0.774
Tobacco
aOR 0.92 1.26 1.00 0.43
95%CI 0.56–1.52 0.54–2.94 0.65–1.54 0.14–1.27
p 0.761 0.575 0.991 0.128
Cannabis
aOR 0.87 1.83 1.02 0.50
95%CI 0.64–1.18 0.65–5.14 0.69–1.51 0.22–1.15
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Alternative model Logisitic Regression**
ASSIST All groups MS* versus VT* VT* versus MDS* MDS* versus MS*
p 0.380 0.248 0.889 0.103
Other drugs
aOR 1.34 0.31 1.15 5.10
95%CI 0.73–2.47 0.11–0.91 0.71–1.85 1.65–15.78
p 0.335 0.033 0.546 0.005
*
MS = Model sequencers; VT = Violators; MDS = Multiple drug seekers
**14 socio-demographic variables were included in the regression models.
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